nach oben

Current Rheumatology Reports

Erschienen in:

01.12.2018 | Osteoarthritis (M Goldring, Section Editor)

Pharmacological Treatment of Pain in Osteoarthritis: A Descriptive Review

verfasst von: Muhammad Hassan Majeed, Syed Ali Amir Sherazi, Douglas Bacon, Zahid H. Bajwa

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Osteoarthritis (OA) is the most common form of arthritis that is characterized by loss of articular cartilage and new formation of bone. Pain and functional disability are common features that lead to disability and poor quality of life. This review discusses the current state of knowledge concerning the treatment of pain in OA, with a focus on pharmacological treatments. This includes the use of non-steroidal anti-inflammatory drugs, acetaminophen, and other disease-modifying agents.

Recent Findings

An updated review of the role of anti-nerve growth factor monoclonal antibodies and other novel agents in the treatment of OA is also presented. In addition, a discussion of current research on biological agents such as small molecules targeting ion channels and G protein-coupled receptors is included. These new pharmacological interventions expand the frontier for treatment of patients with OA.

Summary

The purpose of the review is to provide clinicians with information about the effectiveness of different pharmacological modalities in order to enable them to make the best choices for the treatment of their patients.

Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med [Internet]. 2000;133:635–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11033593.

Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum. 2004;50:341–4.CrossRef

Man GS, Mologhianu G. Osteoarthritis pathogenesis—a complex process that involves the entire joint. J Med Life [Internet]. Carol Davila - University Press; 2014;7:37–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24653755.

Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis [Internet]. 2013;5:77–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23641259.

Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman BN, Aliabadi P, et al. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum [Internet]. 1995;38:1500–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7575700.

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (Lond, Engl). 2016;388:1545–602.CrossRef

Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.CrossRef

Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res (Hoboken). 2016;68:574–80.CrossRef

Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013: statistical brief #204. Healthc. Cost Util. Proj. Stat. Briefs. Agency for Healthcare Research and Quality (US); 2006.

10.

• Fu K, Robbins SR, McDougall JJ. Osteoarthritis: the genesis of pain. Rheumatology. 2018;57:iv43–50. This study provides updated information about the mechanism, types, and mediators of pain in OA. CrossRef

11.

Lluch E, Torres R, Nijs J, Van Oosterwijck J. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain. 2014;18:1367–75.CrossRef

12.

McKelvey L, Shorten GD, O’Keeffe GW. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem. 2013;124:276–89.CrossRef

13.

• Cohen E, Lee YC. A mechanism-based approach to the management of osteoarthritis pain. Curr Osteoporos Rep. 2015;13:399–406. This study provides a clear understanding of the development of pain in OA as well as its management based on the mechanism of the origin of the pain. CrossRef

14.

Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 2012;64:2907–16.CrossRef

15.

Kulkarni B, Bentley DE, Elliott R, Julyan PJ, Boger E, Watson A, et al. Arthritic pain is processed in brain areas concerned with emotions and fear. Arthritis Rheum. 2007;56:1345–54.CrossRef

16.

Bhatia D, Bejarano T, Novo M. Current interventions in the management of knee osteoarthritis. J Pharm Bioallied Sci. 2013;5:30–8.CrossRef

17.

• Geenen R, Overman CL, Christensen R, Åsenlöf P, Capela S, Huisinga KL, et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77:797–807. EULAR narrates evidence and expert opinion in order to provide recommendations concerning the management of pain in OA. PubMed

18.

Anandacoomarasamy A, Caterson I, Sambrook P, Fransen M, March L. The impact of obesity on the musculoskeletal system. Int J Obes. 2008;32:211–22.CrossRef

19.

Bennell KL, Hinman RS. A review of the clinical evidence for exercise in osteoarthritis of the hip and knee. J Sci Med Sport. 2011;14:4–9.CrossRef

20.

Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis. JAMA. 2013;310:1263–73.CrossRef

21.

Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons—a scoping review. Obes Rev. 2014;15:578–86.CrossRef

22.

Majeed MH, Ali AA, Sudak DM. Mindfulness-based interventions for chronic pain: evidence and applications. Asian J Psychiatr. 2018;32:79–83.CrossRef

23.

Majeed MH, Sudak DM. Cognitive behavioral therapy for chronic pain-one therapeutic approach for the opioid epidemic. J Psychiatr Pract. 2017;23:409–14.PubMed

24.

Majeed MH, Ali AA, Sudak DM. Psychotherapeutic interventions for chronic pain: evidence, rationale, and advantages. Int J Psychiatry Med. 2018. https://doi.org/10.1177/009121741879144.

25.

Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329:1317.CrossRef

26.

Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. In: Derry S, editor. Cochrane database syst rev. Chichester: Wiley; 2012. p. CD007400.

27.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet (Lond, Engl). 2017;390:e21–33.CrossRef

28.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Osteoarthr Cartil [Internet]. 2010;18:476–99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20170770.

29.

Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012;41:646–52.CrossRef

30.

Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:2361–72.CrossRef

31.

Citrome L, Weiss–Citrome A. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med. 2012;124:83–93.CrossRef

32.

Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328:991.CrossRef

33.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–5.CrossRef

34.

Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs [Internet]. 1996;52 Suppl 5:13–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8922554.

35.

Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for osteoarthritis. Analg. Osteoarthr. An Updat. 2006 Comp. Eff. Rev. Agency for Healthcare Research and Quality (US); 2011.

36.

Kienzler J-L, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus Oral diclofenac sodium in healthy volunteers. J Clin Pharmacol [Internet]. 2010;50:50–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19841157.

37.

Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S3.CrossRef

38.

Al-Saeed A. Gastrointestinal and cardiovascular risk of nonsteroidal anti-inflammatory drugs. Oman Med J. 2011;26:385–91.CrossRef

39.

Krijthe BP, Heeringa J, Hofman A, Franco OH, Stricker BH. Non-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: a population-based follow-up study. BMJ Open [Internet]. 2014 [cited 2018 Sep 12];4:e004059. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2013-004059.

40.

Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm [Internet]. 2014;71:11–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24779190.

41.

Towheed T, Maxwell L, Judd M, Catton M, Hochberg MC, Wells GA. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;CD004257.

42.

Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63:901–7.CrossRef

43.

Jaeschke H. Acetaminophen: dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig Dis. 2015;33:464–71.CrossRef

44.

Guedes V, Castro JP, Brito I. Topical capsaicin for pain in osteoarthritis: a literature review. Reumatol Clin. 2018;14:40–5.CrossRef

45.

Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain—United States, 2016. JAMA [Internet]. 2016 [cited 2017 Jan 17];315:1624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26977696.

46.

Yi P, Pryzbylkowski P. Opioid induced hyperalgesia. Pain Med. 2015;16(Suppl 1):S32–6.CrossRef

47.

Brat GA, Agniel D, Beam A, Yorkgitis B, Bicket M, Homer M, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ [Internet]. 2018 [cited 2018 Sep 11];j5790. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.j5790.

48.

Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. In: Singh JA, editor. Cochrane database syst rev. Chichester: Wiley; 2015. p. CD005614.

49.

Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75:37–44.CrossRef

50.

Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ. 2004;328:869.CrossRef

51.

Faúndez J, Cotoras P, Irarrázaval S. Are intraarticular steroids effective for knee osteoarthritis? Medwave. 2016;16:e6599.CrossRef

52.

Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013;41:356–64.CrossRef

53.

Cole BJ, Karas V, Hussey K, Merkow DB, Pilz K, Fortier LA. Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. Am J Sports Med. 2017;45:339–46.CrossRef

54.

Karsdal MA, Michaelis M, Ladel C, Siebuhr AS, Bihlet AR, Andersen JR, et al. Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthr Cartil. 2016;24:2013–21.CrossRef

55.

McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283:1469–75.CrossRef

56.

Fransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74:851–8.CrossRef

57.

Hart LE. In knee OA, intraarticular triamcinolone increased cartilage loss and did not differ from saline for knee pain. Ann Intern Med. 2017;167:JC27.CrossRef

58.

Wang C-T, Lin J, Chang C-J, Lin Y-T, Hou S-M. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86–A:538–45.CrossRef

59.

Rutjes AWS, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee. Ann Intern Med. 2012;157:180–91.CrossRef

60.

Anitua E, Sánchez M, Nurden AT, Zalduendo MM, de la Fuente M, Azofra J, et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology (Oxford). 2007;46:1769–72.CrossRef

61.

Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthr Cartil. 2015;23:S8–17.CrossRef

62.

Schnitzer TJ, Ekman EF, Spierings ELH, Greenberg HS, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015;74:1202–11.CrossRef

63.

Kan S-L, Li Y, Ning G-Z, Yuan Z-F, Chen L-X, Bi M-C, et al. Tanezumab for patients with osteoarthritis of the knee: a meta-analysis. PLoS One. 2016;11:e0157105.CrossRef

64.

Tiseo PJ, Kivitz AJ, Ervin JE, Ren H, Mellis SJ. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 2014;155:1245–52.CrossRef

65.

Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther. 2012;14:R199.CrossRef

66.

Mullard A. Drug developers reboot anti-NGF pain programmes. Nat Rev Drug Discov. 2015;14:297–8.CrossRef

67.

Chen J, Li J, Li R, Wang H, Yang J, Xu J, et al. Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials. Pain Med. 2016;18:pnw262.CrossRef

68.

Miller RE, Block JA, Malfait A-M. What is new in pain modification in osteoarthritis? Rheumatology. 2018;57:iv99–iv107.CrossRef

69.

Emery EC, Luiz AP, Wood JN. Na _v 1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets. 2016;20:975–83.CrossRef

70.

Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, et al. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med. 2018;10:eaar3483.CrossRef

Titel: Pharmacological Treatment of Pain in Osteoarthritis: A Descriptive Review
verfasst von: Muhammad Hassan Majeed
Syed Ali Amir Sherazi
Douglas Bacon
Zahid H. Bajwa
Publikationsdatum: 01.12.2018
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 12/2018
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-018-0794-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Opportunistic Screening for Osteoporosis Using Computed Tomography: State of the Art and Argument for Paradigm Shift

Anti-MDA5 Antibody Spectrum in Western World

Systematic Review and Meta-analysis: Mindfulness-Based Interventions for Rheumatoid Arthritis

Bone Microdamage in Acute Knee Injury

Autoinflammatory Disease-Associated Vasculitis/Vasculopathy